Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28919011

Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Oct
First author
Planchard D

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Oct;18(10):1286-1287. doi: 10.1016/S1470-2045(17)30678-2.
    note
    Source null
    related pmid
    28919012
    relationship
    Comment in
  2. citation
    J Thorac Dis. 2018 Feb;10(2):589-592. doi: 10.21037/jtd.2018.01.129.
    note
    Source null
    related pmid
    29607117
    relationship
    Comment in

Authors and identifiers

  1. name
    Planchard D
    type
    Author
  2. name
    Smit EF
    type
    Author
  3. name
    Groen HJM
    type
    Author
  4. name
    Mazieres J
    type
    Author
  5. name
    Besse B
    type
    Author
  6. name
    Helland Å
    type
    Author
  7. name
    Giannone V
    type
    Author
  8. name
    D'Amelio AM Jr
    type
    Author
  9. name
    Zhang P
    type
    Author
  10. name
    Mookerjee B
    type
    Author
  11. name
    Johnson BE
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Planchard D
    type
    Author
  2. name
    Smit EF
    type
    Author
  3. name
    Groen HJM
    type
    Author
  4. name
    Mazieres J
    type
    Author
  5. name
    Besse B
    type
    Author
  6. name
    Helland Å
    type
    Author
  7. name
    Giannone V
    type
    Author
  8. name
    D'Amelio AM Jr
    type
    Author
  9. name
    Zhang P
    type
    Author
  10. name
    Mookerjee B
    type
    Author
  11. name
    Johnson BE
    type
    Author
bibliography ids
  1. nci-bib-2db0a306b3bf2cc32101f3e2
book metadata
content sha256
ab91dbf9f345224121b7a5eed70eeca92501edeacdb1c89bccc9d87da2f12205
document type
citation
dois
  1. 10.1016/S1470-2045(17)30679-4
electronic publication date
display
2017 Sep 11
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28919011
immutable id
pubmed:28919011@ab91dbf9f345224121b7a5eed70eeca92501edeacdb1c89bccc9d87da2f12205
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1307-1316
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Oct;18(10):1286-1287. doi: 10.1016/S1470-2045(17)30678-2.
    note
    Source null
    related pmid
    28919012
    relationship
    Comment in
  2. citation
    J Thorac Dis. 2018 Feb;10(2):589-592. doi: 10.21037/jtd.2018.01.129.
    note
    Source null
    related pmid
    29607117
    relationship
    Comment in
outcomes validated
false
pmid
28919011
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
10317700ca389f7020f502fbb293722a7c7a4b1106e29fdb7acf790c2f15e001
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct
precision
month
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Controlled Clinical Trial
  3. Journal Article
  4. Multicenter Study
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28919011/
title
Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Preserved source evidence · Not medical advice